Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing elective higher, lower or mixed gastrointestinal endoscopy at Hospital de San Jose, Bogota, between January and December 2010.~* Be between 18 and 70 years old.~* American Society of Anesthesiology Physical Status classification between 1 and 3.~* Provide written informed consent.~Exclusion Criteria:~* Patients with difficult airway indicators.~* Pregnant women.~* Patients with chronic pain.~* Chronic opioid or benzodiazepine users (\>3 months).~* Allergy history to remifentanil or propofol or eggs.~* Psychoactive drug users.~* Smokers (\> 5 cigarettes per day in the previous 3 months).~* Body mass index \> 30.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria.
- Propofol (Type: ACTIVE_COMPARATOR): Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).